Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

KalVista Pharmaceuticals (KALV) Receivables Refunds (2017 - 2025)

KalVista Pharmaceuticals' Receivables Refunds history spans 8 years, with the latest figure at $1.4 million for Q2 2025.

  • On a quarterly basis, Receivables Refunds fell 83.54% to $1.4 million in Q2 2025 year-over-year; TTM through Apr 2025 was $1.4 million, a 83.54% decrease, with the full-year FY2025 number at $1.4 million, down 83.54% from a year prior.
  • Receivables Refunds hit $1.4 million in Q2 2025 for KalVista Pharmaceuticals, down from $11.4 million in the prior quarter.
  • Over the last five years, Receivables Refunds for KALV hit a ceiling of $20.0 million in Q4 2023 and a floor of $263000.0 in Q1 2024.
  • Historically, Receivables Refunds has averaged $8.8 million across 4 years, with a median of $8.4 million in 2024.
  • Biggest five-year swings in Receivables Refunds: tumbled 37.07% in 2021 and later tumbled 95.17% in 2024.
  • Tracing KALV's Receivables Refunds over 4 years: stood at $10.4 million in 2021, then surged by 92.08% to $20.0 million in 2023, then crashed by 42.85% to $11.4 million in 2024, then plummeted by 87.89% to $1.4 million in 2025.
  • Business Quant data shows Receivables Refunds for KALV at $1.4 million in Q2 2025, $11.4 million in Q4 2024, and $965000.0 in Q4 2024.